ADPT — Adaptive Biotechnologies Corporation stock price, charts and financials
QT77Adaptive Biotechnologies CorporationAdaptive Biotechnologies Corporation (NASDAQ: ADPT) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.41 | Insider Own | 5.88% | Shs Outstand | 160.04M | Perf Week | 10.46% |
| Market Cap | 3.99B | Forward P/E | - | EPS next Y | -0.18 | Insider Trans | -45.92% | Shs Float | 155.20M | Perf Month | 14.36% |
| Enterprise Value | 4.23B | PEG | - | EPS next Q | -0.11 | Inst Own | - | Short Float | 7.34% | Perf Quarter | 69.71% |
| Income | -64.64M | P/S | 12.95 | EPS this Y | -32.93% | Inst Trans | - | Short Ratio | 4.49 | Perf Half Y | 51.37% |
| Sales | 308.08M | P/B | 27.51 | EPS next Y | 67.66% | ROA | -9.97% | Short Interest | 11.40M | Perf YTD | 53.51% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -32.64% | 52W High | 25.96 -0.12% | Perf Year | 113.26% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -6.67% | 52W Low | 11.86 118.68% | Perf 3Y | 213.19% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 14.40% 23.10% | Gross Margin | 75.44% | Volatility | 5.03% 5.86% | Perf 5Y | -32.00% |
| Dividend TTM | - | EV/Sales | 13.73 | EPS Y/Y TTM | 62.04% | Oper. Margin | -12.16% | ATR (14) | 1.35 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.68 | Sales Y/Y TTM | 72.63% | Profit Margin | -20.73% | RSI (14) | 63.61 | Recom | 2.47 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.79 | EPS Q/Q | -47.06% | SMA20 | 9.22% | Beta | 2.07 | Target Price | 24.38 |
| Payout | 0.00% | Debt/Eq | 2.87 | Sales Q/Q | 22.03% | SMA50 | 23.23% | Rel Volume | 0.87 | Prev Close | 24.93 |
| Employees | 624 | LT Debt/Eq | 1.19 | Earnings | Nov 04 | SMA200 | 48.67% | Avg Volume | 2.86M | Price | 25.93 |
| IPO Date | Jun 27, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -87.11% 9.35% | Net Debt/EBITDA | -15.07 | Volume | 2,495,015 | Change | 3.99% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-04-26 | Reiterated | Piper Sandler | Overweight | $21 → $28 |
| Jul-30-26 | Reiterated | BTIG | Buy | $22 → $25 |
| Jul-30-26 | Reiterated | Guggenheim | Buy | $22 → $25 |
| Jul-09-26 | Reiterated | Morgan Stanley | Equal Weight | $21 → $20 |
| Jun-29-26 | Reiterated | Guggenheim | Buy | $21 → $22 |
| Feb-06-26 | Reiterated | Piper Sandler | Overweight | $20 → $21 |
| Feb-06-26 | Reiterated | BTIG | Buy | $5.00 → $22 |
| Jan-26-26 | Reiterated | Guggenheim | Buy | $20 → $21 |
| Dec-01-25 | Reiterated | Morgan Stanley | Equal Weight | $18 → $21 |
| Oct-15-25 | Reiterated | Piper Sandler | Overweight | $14 → $20 |
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 309 | 277 | 179 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 76 | 71 | 72 | — | — | — | — | — | — | |
| Gross Profit | 232 | 206 | 107 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 180 | 167 | 158 | — | — | — | — | — | — | |
| Research and Development | 89 | 94 | 103 | — | — | — | — | — | — | |
| Other Operating Expense | 1 | 2 | 8 | — | — | — | — | — | — | |
| Operating Income | -38 | -57 | -163 | — | — | — | — | — | — | |
| Interest Expense | 12 | 12 | 12 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -15 | 9 | 15 | — | — | — | — | — | — | |
| Net Income Before Taxes | -64 | -59 | -160 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -64 | -59 | -159 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -64 | -59 | -160 | — | — | — | — | — | — | |
| Net Income | -64 | -59 | -159 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.41 | -0.39 | -1.08 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.41 | -0.39 | -1.08 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.41 | -0.39 | -1.08 | — | — | — | — | — | — | |
| EBITDA | -15 | -30 | -129 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 13.26 | 8.91 | 4.93 | — | — | — | — | — | — | |
| Gross Margin | 75.08 | 74.37 | 59.78 | — | — | — | — | — | — | |
| Operating Margin | -12.30 | -20.58 | -91.06 | — | — | — | — | — | — | |
| Net Margin | -20.71 | -21.30 | -88.83 | — | — | — | — | — | — | |
| Shares Outstanding | 158 | 152 | 147 | — | — | — | — | — | — | |
| Market Capitalization | 4,096 | 2,468 | 882 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| BOBULSKY SUSAN | Chief Commercial Officer, MRD | Jul 30 '26 | Sale | 24.00 | 1,299 | 31,176 | 399,989 | Aug 03 |
| ROBINS HARLAN S | Chief Scientific Officer | Jul 21 '26 | Sale | 21.89 | 492,400 | 10,780,409 | 812,058 | Jul 23 |
| ROBINS HARLAN S | Chief Scientific Officer | Jul 21 '26 | Option Exercise | 6.55 | 284,800 | 1,865,440 | 1,304,458 | Jul 23 |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD | Jul 16 '26 | Sale | 23.00 | 5,000 | 115,000 | 401,288 | Jul 20 |
| LO FRANCIS | Chief People Officer | Jul 15 '26 | Option Exercise | 8.91 | 105,762 | 942,691 | 336,475 | Jul 17 |
| LO FRANCIS | Chief People Officer | Jul 15 '26 | Sale | 22.59 | 105,762 | 2,389,164 | 230,713 | Jul 17 |
| ROBINS HARLAN S | Chief Scientific Officer | Jul 02 '26 | Sale | 22.01 | 386,240 | 8,501,149 | 1,019,658 | Jul 07 |
| LO FRANCIS | Chief People Officer | Jul 02 '26 | Option Exercise | 9.46 | 37,863 | 358,356 | 275,551 | Jul 06 |
| LO FRANCIS | Chief People Officer | Jul 02 '26 | Sale | 22.59 | 44,838 | 1,012,890 | 230,713 | Jul 06 |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD | Jul 01 '26 | Sale | 22.00 | 487 | 10,714 | 406,288 | Jul 06 |
| LO FRANCIS | Chief People Officer | Jul 01 '26 | Option Exercise | 8.04 | 37,758 | 303,530 | 288,692 | Jul 06 |
| LO FRANCIS | Chief People Officer | Jul 01 '26 | Sale | 22.45 | 51,004 | 1,144,793 | 237,688 | Jul 06 |
| BENZENO SHARON | Chief Commercial Ofc Imm Med | Jun 29 '26 | Option Exercise | 7.28 | 103,295 | 751,602 | 376,046 | Jun 30 |
| BENZENO SHARON | Chief Commercial Ofc Imm Med | Jun 29 '26 | Sale | 21.14 | 154,768 | 3,271,796 | 221,278 | Jun 30 |
| BENZENO SHARON | Chief Commercial Ofc Imm Med | Jun 26 '26 | Sale | 21.00 | 11,034 | 231,714 | 272,751 | Jun 30 |